Enfortumab Vedotin Plus Pembrolizumab Maintains Survival Adv

Enfortumab vedotin plus pembrolizumab showed consistent overall survival and progression-free survival benefit in all patients enrolled in EV-302.

Related Keywords

Perez Valderrama , Michiels Van , Bristol Myers Squibb , Astellas Pharma , Novartis , Gilead Sciences , Cancers Symposium , Der Heijden , Enfortumab Vedotin , Pembrolizumab , Padcev , Keytruda , Asco Gu , Genitourinary Cancers Symposium , Ev 302 , Keynote A39 Trial , Michiels Van Der Heijden , D , Phd , Netherlands Cancer Institute , Subgroup Analysis , Urothelial Carcinoma ,